Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Oklahoma
M.D. Anderson Cancer Center
Mayo Clinic
Eli Lilly and Company
University Hospital, Linkoeping
University of Nebraska
Eli Lilly and Company
Astellas Pharma Inc
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Astellas Pharma Inc
M.D. Anderson Cancer Center
Guardant Health, Inc.
Nagoya University
Emory University
VA Office of Research and Development
University of Chicago
Fox Chase Cancer Center
Astellas Pharma Inc
Eli Lilly and Company
National Cancer Institute (NCI)
Changhai Hospital
Altor BioScience
Changhai Hospital
University of California, San Francisco
National Cancer Institute (NCI)
Hoosier Cancer Research Network
The Affiliated Hospital of Qingdao University
pharmaand GmbH
Yonsei University
Mayo Clinic
Wake Forest University Health Sciences
University Health Network, Toronto
Changhai Hospital
M.D. Anderson Cancer Center
City of Hope Medical Center
Yonsei University
Karolinska University Hospital
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
Cardiff University
Karolinska University Hospital
Mansoura University
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
AEterna Zentaris
Asan Medical Center